Professor James P. Allison was born on 7 August 1948 in Alice, Texas, United States of America. He obtained his BS in Microbiology in 1969, and latter in 1973 his PHD in Biological Sciences from the University of Texas, Austin, TX, USA. He did his postgraduate fellowship in Molecular Immunology at Scripps Clinic and Research Foundation, La Jolla, CA, USA.
Professor Allison has assumed many academic and administrative positions during his fruitful career. Currently he is the “Vivian L. Smith Distinguished” Chair of the Department of Immunology, & Director of the Parker Institute for Cancer Immunotherapy at The University of Texas MD Anderson Cancer Center, Houston, TX., USA.
Professor Allison’s vast contributions to humanity and medicine through his research in the field of Immunotherapy for cancer where he has published over 250 peer reviewed articles in reputable scientific journals. Amongst his publications where the articles titled “Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells”, “CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation”, and “CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells”.
In addition to being a member of the editorial board of many reputable scientific journals, professor Allison has participated in various conferences and exhibitions in his field as well as supervising many graduate students. His work has been recognized by over 60 awards and honors including the Sjoberg Prize for Cancer Research by Royal Swedish Academy of Sciences and the Wolf Prize for Medicine from Wolf Foundation in 2017.
Professor James P. Allison, was awarded the prize, For his outstanding contribution to the development of the field of immunotherapy of cancer. He identified CTLA4 as an inhibitory receptor of T-cells and pioneered the development of immune checkpoint inhibitors for the treatment of a range of cancers.